Royal Bank of Canada
ADCT icon

Royal Bank of Canada’s ADC Therapeutics ADCT Stock Holding History

Royal Bank of Canada’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23K Sell
6,224
-4,039
-39% -$15.9K ﹤0.01% 5829
2025
Q4 		$36K Buy
10,263
+1,453
+16% +$5.9K ﹤0.01% 5717
2025
Q3 		$36K Buy
8,810
+3,807
+76% +$12K ﹤0.01% 5957
2025
Q2 		$13K Sell
5,003
-75
-1% -$158 ﹤0.01% 6397
2025
Q1 		$7K Sell
5,078
-5,097
-50% -$8.66K ﹤0.01% 6244
2024
Q4 		$20K Sell
10,175
-2,743
-21% -$7.18K ﹤0.01% 6100
2024
Q3 		$40K Buy
12,918
+3,479
+37% +$11K ﹤0.01% 5801
2024
Q2 		$30K Buy
9,439
+6,409
+212% +$25.5K ﹤0.01% 5883
2024
Q1 		$14K Sell
3,030
-1,000
-25% -$3.69K ﹤0.01% 6051
2023
Q4 		$7K Sell
4,030
-4,055
-50% -$3.74K ﹤0.01% 6573
2023
Q3 		$8K Sell
8,085
-2,039
-20% -$2.71K ﹤0.01% 6481
2023
Q2 		$22K Buy
10,124
+3,121
+45% +$7.02K ﹤0.01% 6155
2023
Q1 		$14K Buy
7,003
+1,373
+24% +$5.07K ﹤0.01% 6160
2022
Q4 		$21K Buy
5,630
+3,639
+183% +$14.6K ﹤0.01% 6275
2022
Q3 		$9K Buy
1,991
+500
+34% +$3.62K ﹤0.01% 6456
2022
Q2 		$12K Buy
1,491
+600
+67% +$5.68K ﹤0.01% 6292
2022
Q1 		$13K Buy
891
+412
+86% +$6.54K ﹤0.01% 6822
2021
Q4 		$10K Sell
479
-398
-45% -$9.6K ﹤0.01% 7038
2021
Q3 		$24K Buy
877
+400
+84% +$10.2K ﹤0.01% 6602
2021
Q2 		$12K Buy
477
+50
+12% +$1.16K ﹤0.01% 6793
2021
Q1 		$11K Buy
+427
New +$12.4K ﹤0.01% 6746
2020
Q4 		– Sell
-22
Closed -$1K – 7033
2020
Q3 		$1K Buy
+22
New +$952 ﹤0.01% 6380

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada's ADCT Position: Q1 2026 in Review

Royal Bank of Canada reduced its ADC Therapeutics (ADCT) stake by 39% in Q1 2026, selling an estimated $15.9K and leaving 6,224 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5829.

Royal Bank of Canada first reported a position in ADCT in Q3 2020 and has held it in 22 quarters since. The position peaked at $40K in Q3 2024. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Royal Bank of Canada held 6,224 shares of ADC Therapeutics worth $23K as of Q1 2026.
  • Royal Bank of Canada sold 4,039 ADC Therapeutics shares in Q1 2026, an estimated $15.9K.
  • ADC Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5829 holding.
  • Royal Bank of Canada first reported a position in ADC Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's ADC Therapeutics position peaked at $40K in Q3 2024.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.